RAIDS
Rational molecular Assessments and Innovative Drug Selection
| Coordinatore | INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 7˙687˙882 € |
| EC contributo | 5˙999˙642 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-10-01 - 2017-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT CURIE
Organization address
address: 26, rue d'Ulm contact info |
FR (PARIS) | coordinator | 1˙587˙867.78 |
| 2 |
SEQOMICS BIOTECHNOLOGIA KORLATOLT FELELOSSEGU TARSASAG
Organization address
address: ZOLDFASI UT 29 contact info |
HU (SZEGED) | participant | 945˙200.00 |
| 3 |
AMSTERDAM BIOTHERAPEUTICS UNIT
Organization address
address: Louwesweg 6 contact info |
NL (Amsterdam) | participant | 815˙496.00 |
| 4 |
INSTITUT GUSTAVE ROUSSY
Organization address
address: Rue Camille Desmoulins 39 contact info |
FR (VILLEJUIF) | participant | 545˙692.80 |
| 5 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 537˙572.80 |
| 6 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 372˙134.40 |
| 7 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 318˙216.36 |
| 8 |
HANNOVER CLINICAL TRIAL CENTER GMBH
Organization address
address: CARL NEUBERG STR 1 K 27 OE 9751 contact info |
DE (HANNOVER) | participant | 257˙862.00 |
| 9 |
ALMA CONSULTING GROUP SAS
Organization address
address: Domaine des Bois d'Houlbec contact info |
FR (HOULBEC COCHEREL) | participant | 257˙215.16 |
| 10 |
QUANTICSOFT SARL
Organization address
address: RUE DU CHERCHE MIDI 86 contact info |
FR (PARIS) | participant | 119˙681.00 |
| 11 |
INSTITUT ZA ONKOLOGIJU VOJVODINE-ONCOLOGY INSTITUTE OF VOJVODINA IOV
Organization address
address: PUT DOKTORA GOLDMANA 4 contact info |
RS (SREMSKA KAMENICA) | participant | 115˙952.40 |
| 12 |
INSTITUTIA MEDICO-SANITARA PUBLICA INSTITUTUL ONCOLOGIC
Organization address
address: STRADA TESTEMITEANU 30 contact info |
MD (CHISINAU) | participant | 60˙645.00 |
| 13 |
KLINIKEN ESSEN-MITTE EVANG. HUYSSENS-STIFTUNG/KNAPPSCHAFT GEMEINNUTZIGE GMBH
Organization address
address: HENRICISTRASSE 92 contact info |
DE (ESSEN) | participant | 35˙926.00 |
| 14 |
Nome Ente NON disponibile
Organization address
address: Domstrasse 11 contact info |
DE (GREIFSWALD) | participant | 23˙370.70 |
| 15 |
TEO HEALTH SA
Organization address
address: IULIU MANIU 49 CORP VECHI contact info |
RO (BRASOV) | participant | 6˙810.00 |
| 16 |
Keocyt SAS
Organization address
address: rue Chauvelot 29 contact info |
FR (MALAKOFF) | participant | 0.00 |
| 17 |
STICHTING ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cervical cancer (CC) is the second most common cause of cancer deaths in women worldwide. The main objective of the RAIDs project is to use this model system which is accessible to repeat biopsies to learn how to stratify patients into targeted therapies. The patients’ tumors will be classified into molecular subtypes based on their molecular profile by use of high-throughput technologies (sequencing, RPPA) combined with integrative bioinformatics analysis. Stratification is a learning process which will need constant readaptation. It will rely on prognostic and predictive biomolecular information gained from patients who will receive either standard therapy (the cognitive cohort) or patients who receive (first generation) targeted therapy. Bioinformatics will be an essential tool to allow integrative genome/proteome analysis and provide functional interpretation of the results at each step. Machine learning techniques will be used to select the most reliable biomarkers. These tools will be used to predict response to cc treatment or progression. Moreover, systems biology approaches will be used to unravel the gene regulatory networks and signaling pathways involved in the tumor progression and should be helpful to select predictive biomarkers and putative drug targets. Tumor material will be sampled before and following standard therapy or therapeutic HPV vaccination and/or novel targeted drug treatments. Clinical annotation by imaging methods as well as through biomarkers will have quality control procedures and relevant statistical models will be applied. RAIDS is a multidisciplinary approach integrating genomic studies, protein arrays, viral genotyping and immunohistochemical investigations on CC cells and tissues between academic clinical centers and SME’s . The project is expected to provide new tools for early diagnosis and targeted treatments exploited by SMEs and to accelerate innovation of CC therapy and improve quality of life.'